

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

### Data Insights: Covid-2019 Monitor

Thursday, June 10, 2021

## The global scorecard



#### For more information contact us: Donald Luskin: 312 273 6766 don@trendmacro.com

Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

## The US scorecard



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

Rolling out the vaccines in the US and the World												
US overall Total		otal					Today		Immunity	Full	Partial	
Doses distributed		385,034,145						+0.396	million	US	42.2%	51.5%
Doses administered		314,001,206					+0.852 million		UK	42.0%	60.0%	
Administered		One dose		% Рор	lm	mune	% рор	New immune today		France	19.1%	41.9%
Total population		176,589,967		53%	1	144,958,248	43%	+0.550 million		Spain	24.7%	43.4%
Age 12 to 17		7,128,135		28%		3,455,427	14%	+0.182 million		Germany	23.7%	46.7%
Age 18 to 64		120,451,926		59%		98,554,893 48%		+0.312	+0.312 million		22.3%	45.4%
Age 65 and over		48,886,416		89%		42,912,018	3 78% +0.051 millio		million	Australia	2.6%	18.4%
۲%۲										Israel	59.4%	63.2%
L	4%					At today's	dosing p	ace,		Canada	9.1%	63.2%
				e		every Am	American >18 immune in		in	Japan	4.1%	12.0%
Moderna	Dfizer	State				10	1 1 1			Africa	0.8%	2.2%
42%	54%		ale			137	+ UO	IYS		India	3.3%	13.9%
3470		Immunities distributed		by Dec 19, 2021					Brazil	11.0%	24.2%	
		as % population**			67.6% of population 3			>18 immunized		Global data differ	rs from sources,	timing
AK At least parti		tial immunity			14.1% previously tested positive			;	China NA	ME		
60.0% as % p		opulation	Best		81.7% vs 60% adult herd im			munity*		71.0%		
46.9% Full immuni		munity			R				·	64.5%		
40.2%		as % population		Mic	Idle						56.8%	
						WI				VT	NH	
				Wo	orst	54.1%				76.8%	69.3%	
						52.0%				71.7%	60.8%	
						45.8%			59.5%	52.3%		
	WA	ID	MT	ND	MN	IL	MI		NY	MA		
	62.9%	48.5%	54.4%	48.4%	59.9%	60.1%	60.2%		62.8%	72.3%		
	58.1%	38.2%	46.3%	42.7%	55.3%	56.4%	49.7%		57.2%	68.0%		
	49.0%	33.6%	40.0%	37.1%	47.6%	41.5%	43.6%		48.9%	56.8%		
	OR	NV	WY	SD	IA	IN	OH	PA	NJ	CT	RI	
	68.7%	51.0%	46.9%	56.8%	56.5%	51.7%	54.7%	63.9%	66.4%	68.3%	73.1%	
	56.2%	46.6%	37.8%	48.8%	50.0%	42.6%	46.8%	59.9%	61.8%	64.5%	62.2%	
	48.0%	38.1%	32.6%	43.1%	45.1%	36.7%	41.5%	45.7%	50.8%	55.7%	53.8%	
	CA	UT	CO	NE	M0	KY	WV	VA	MD	DE		
	64.1%	52.0%	62.5%	55.6%	51.3%	51.9%	55.0%	62.1%	71.6%	67.6%		
	58.3%	46.0%	55.5%	49.3%	43.0%	47.3%	41.4%	56.5%	58.7%	55.9%		
	45.3%	33.6%	47.1%	43.6%	35.4%	39.5%	34.7%	46.9%	50.2%	44.9%		
		AZ	NM	KS	AR	TN	NC	SC	DC			
		57.3%	58.4%	54.7%	49.2%	47.9%	57.7%	53.2%	78.2%			
		47.3%	58.7%	47.5%	40.3%	39.8%	44.0%	41.7%	58.1%			
		37.2%	49.0%	39.3%	32.0%	32.5%	37.0%	35.2%	47.8%			
				OK	LA	MS	AL	GA		-		
				52.9%	45.1%	46.7%	50.2%	54.1%				
				42.1%	36.5%	34.8%	36.2%	41.3%				
				34.4%	32.1%	27.9%	29.5%	33.8%				
HI				TX					FL	ן נ	PR	
69.9%			56.7%					60.1%		63.9%		
67.8%				45.4%	50.69						52.9%	
48.7%				37.0%	As of Jun 9 40.7%				40.7%		39.4%	

### Dolling out th

\* Includes persons >18 fully immunized or previosuly tested positive, no overlap. Disregards untested positives, natural immunities.

\*\* One dose of Pfizer/Moderna counts as half an immunity, one dose of J&J as a full immunity

Source: CDC, CDC, Our World in Data, TrendMacro calculations



Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

## Recommended reading

# Necessity of COVID-19 vaccination in previously

infected individuals Nabin K. Shrestha et al. *medRvx* June 5, 2021

### <u>Cleveland Clinic Statement on Previous COVID-19</u> Infection Research

*Cleveland Clinic* June 9, 2021

# Johnson & Johnson vaccine effective against variants: study

Justine Coleman *The Hill* June 9, 2021

### Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter et al. *Nature* June 9, 2021

## Meme of the day

One Fate, Two Fates. Red States, Blue States: New Data Reveal a 432-Hour In-Person Learning Gap Produced by the Politics of Pandemic Schooling Asher Lehrer-Small *T74* June 9, 2021

Education Through the Pandemic: From Tennessee's Push to Woo New Teachers Through Higher Salaries to Indiana's Decline in HS Grads Seeking Out More Education, 11 Ways States Are Confronting COVID Slide Joshua Parrish *T74* 

June 8, 2021

## The Power of Natural Immunity

Marty Makary *Wall Street Journal* June 8, 2021



Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale* 

Source: Johns Hopkins, TrendMacro calculations

![](_page_7_Figure_0.jpeg)

The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality* 

Source: Johns Hopkins, Trend Macro calculations

![](_page_8_Figure_0.jpeg)

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst

![](_page_9_Figure_1.jpeg)

Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst

![](_page_10_Figure_1.jpeg)

Source: Covid Act Now, TrendMacro calculations

# From Ground Zero to the Rio Grande

![](_page_11_Figure_1.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_12_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_13_Figure_0.jpeg)

Patient zero... and then everyone else

## Impact in the largest economies

![](_page_14_Figure_1.jpeg)

![](_page_15_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_16_Figure_0.jpeg)

## Impact in other hot-spots

![](_page_17_Figure_1.jpeg)

![](_page_18_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_19_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_20_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations